Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine · 2005 · 5.4K citations · Full text

Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties

Travis T. Wager, Xinjun Hou, Patrick R. Verhoest et al. · ACS Chemical Neuroscience · 2010 · 1K citations

Pharmaceutical Science, Drug Target, Engineering +22

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Sauveur-Michel Maira, Sabina Pecchi, Alan Huang et al. · Molecular Cancer Therapeutics · 2011 · 524 citations

Pharmacotherapy, Different Selectivity Profile, Chemical Biology +26

BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas

Stefan M. Pfister, Wibke G. Janzarik, Marc Remke et al. · Journal of Clinical Investigation · 2008 · 511 citations · Full text

Genetics, Pathology, Mapk Pathway Activation +20

Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

Daphne A. Haas-Kogan, Michael D. Prados, Tarık Tihan et al. · JNCI Journal of the National Cancer Institute · 2005 · 465 citations · Full text